Cystic fibrosis

Source: Wikipedia, the free encyclopedia.

Cystic fibrosis
Other namesMucoviscidosis
Northern European)[1]
1 out of 30 in the United States is a carrier[citation needed]
Deaths40 percent of the population is affected

Cystic fibrosis (CF) is a

symptoms may include sinus infections, poor growth, fatty stool, clubbing of the fingers and toes, and infertility in most males.[1] Different people may have different degrees of symptoms.[1]

Cystic fibrosis is inherited in an

autosomal recessive manner.[1] It is caused by the presence of mutations in both copies (alleles) of the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein.[1] Those with a single working copy are carriers and otherwise mostly healthy.[3] CFTR is involved in the production of sweat, digestive fluids, and mucus.[10] When the CFTR is not functional, secretions that are usually thin instead become thick.[11] The condition is diagnosed by a sweat test and genetic testing.[1] The sweat test measures sodium concentration, as people with cystic fibrosis have abnormally salty sweat, which can often be tasted by parents kissing their children. Screening of infants at birth takes place in some areas of the world.[1]

There is no known cure for cystic fibrosis.

developed world,[5][13] with a median of 40.7 years.[14] Lung problems are responsible for death in 70% of people with cystic fibrosis.[1]

CF is most common among people of

Dorothy Andersen in 1938, with descriptions that fit the condition occurring at least as far back as 1595.[9] The name "cystic fibrosis" refers to the characteristic fibrosis and cysts that form within the pancreas.[9][15]

Video summary (script)

Signs and symptoms

Health problems associated with cystic fibrosis

Cystic fibrosis typically manifests early in life. Newborns and infants with cystic fibrosis tend to have frequent, large, greasy stools (a result of malabsorption) and are underweight for their age.[16]: Clinical Manifestations  15–20% of newborns have their small intestine blocked by meconium, often requiring surgery to correct.[16]: Clinical Manifestations  Newborns occasionally have neonatal jaundice due to blockage of the bile ducts.[16]: Clinical Manifestations  Children with cystic fibrosis lose excessive salt in their sweat, and parents often notice salt crystallizing on the skin, or a salty taste when they kiss their child.[16]: Clinical Manifestations 

The primary cause of

digital clubbing, cyanosis, coughing up blood, pulmonary heart disease, and collapsed lung (atelectasis or pneumothorax).[16]
: Respiratory Tract 

In rare cases, cystic fibrosis can manifest itself as a coagulation disorder. Vitamin K is normally absorbed from breast milk, formula, and later, solid foods. This absorption is impaired in some CF patients. Young children are especially sensitive to vitamin K malabsorptive disorders because only a very small amount of vitamin K crosses the placenta, leaving the child with very low reserves and limited ability to absorb vitamin K from dietary sources after birth. Because clotting factors II, VII, IX, and X are vitamin K–dependent, low levels of vitamin K can result in coagulation problems. Consequently, when a child presents with unexplained bruising, a coagulation evaluation may be warranted to determine whether an underlying disease is present.[18]

Lungs and sinuses

Burkholderia cepacia
complex

Lung disease results from clogging of the airways due to mucus build-up, decreased

bilevel positive airway pressure machines or ventilators.[21] Staphylococcus aureus, Haemophilus influenzae, and Pseudomonas aeruginosa are the three most common organisms causing lung infections in CF patients.[20]: 1254  In addition, opportunistic infection due to Burkholderia cepacia complex can occur, especially through transmission from patient to patient.[22]

In addition to typical bacterial infections, people with CF more commonly develop other types of lung diseases. Among these is allergic bronchopulmonary aspergillosis, in which the body's response to the common fungus Aspergillus fumigatus causes worsening of breathing problems. Another is infection with Mycobacterium avium complex, a group of bacteria related to tuberculosis, which can cause lung damage and do not respond to common antibiotics.[23]

The mucus in the

paranasal sinuses is equally thick and may also cause blockage of the sinus passages, leading to infection. This may cause facial pain, fever, nasal drainage, and headaches. Individuals with CF may develop overgrowth of the nasal tissue (nasal polyps) due to inflammation from chronic sinus infections.[24] Recurrent sinonasal polyps can occur in 10% to 25% of CF patients.[20]: 1254  These polyps can block the nasal passages and increase breathing difficulties.[25][26]

Cardiorespiratory complications are the most common causes of death (about 80%) in patients at most CF centers in the United States.[20]: 1254 

Gastrointestinal

Digestive problems are also prevalent in individuals with CF. Approximately 15%-20% of newborns diagnosed with CF experience intestinal blockage (

meconium ileus), and other digestive issues may arise due to mucus accumulation in the pancreas.[27] Consequently, there is impaired insulin production, leading to cystic fibrosis-related diabetes mellitus. Moreover, enzyme transport disruption from the pancreas to the intestines results in digestive problems such as recurrent diarrhea or weight loss.[28]

In cystic fibrosis, there is impaired chloride secretion due to the mutation of CFTR. This disrupts the ionic balance, causes impaired bicarbonate secretion, and alters the pH. The pancreatic enzymes that work in a specific pH range cannot act as the chyme is not neutralized by bicarbonate ions. This causes impairment of the digestion process.[29]

The thick mucus seen in the lungs has a counterpart in thickened secretions from the

exocrine movement of the digestive enzymes into the duodenum and result in irreversible damage to the pancreas, often with painful inflammation (pancreatitis).[30] The pancreatic ducts are totally plugged in more advanced cases, usually seen in older children or adolescents.[20] This causes atrophy of the exocrine glands and progressive fibrosis.[20]

In addition, protrusion of internal rectal membranes (rectal prolapse) is more common, occurring in as many as 10% of children with CF,[20] and it is caused by increased fecal volume, malnutrition, and increased intra–abdominal pressure due to coughing.[31]

Individuals with CF also have difficulties absorbing the fat-soluble vitamins A, D, E, and K.[32]

In addition to the pancreas problems, people with CF experience more

inspissated) and can cause bloating, pain, and incomplete or complete bowel obstruction.[34][32]

ΔF508/ΔF508).[20]: 1253  It occurs in 10–15% of patients with one "severe" and one "mild" CFTR mutation where little CFTR activity still occurs, or where two "mild" CFTR mutations exist.[20]: 1253  In these milder cases, a sufficient pancreatic exocrine function is still present so enzyme supplementation is not required.[20]: 1253  Usually, no other GI complications occur in pancreas-sufficient phenotypes, and in general, such individuals usually have excellent growth and development.[20]: 1254  Despite this, idiopathic chronic pancreatitis can occur in a subset of pancreas-sufficient individuals with CF, and is associated with recurrent abdominal pain and life-threatening complications.[20]

Liver diseases are another common complication in CF patients. The prevalence in studies ranged from 18% at age two to 41% at age 12, with no significant increase thereafter.[35] Another study found that males with CF are more prone to liver diseases compared to females, and those with meconium ileus have an increased risk of liver diseases.[36]

Thickened secretions also may cause liver problems in patients with CF. Bile secreted by the liver to aid in digestion may block the bile ducts, leading to liver damage. Impaired digestion or absorption of lipids can result in steatorrhea. Over time, this can lead to scarring and nodularity (cirrhosis). The liver fails to rid the blood of toxins and does not make important proteins, such as those responsible for blood clotting.[37][38] Liver disease is the third-most common cause of death associated with CF.[20]

Around 5–7% of people experience

liver damage severe enough to cause symptoms: typically gallstones causing biliary colic.[16]
: Biliary Tract 

Endocrine

The pancreas contains the

type 2 diabetes, and is one of the principal nonpulmonary complications of CF.[40]

Vitamin D is involved in calcium and phosphate regulation. Poor uptake of vitamin D from the diet because of malabsorption can lead to the bone disease osteoporosis in which weakened bones are more susceptible to fractures.[41]

Infertility

Infertility affects both men and women. At least 97% of men with cystic fibrosis are infertile, but not sterile, and can have children with assisted reproductive techniques.

a lack of menstruation.[45]

Causes

Cystic fibrosis has an autosomal recessive pattern of inheritance.

CF is caused by having no functional copies (alleles) of the

autosomal recessive disease.[49]

The CFTR gene, found at the q31.2

PDZ domain interaction.[50] Most CFTR in lung passages is produced by rare ion-transporting cells that regulate mucus properties.[51]

In addition, the evidence is increasing that genetic modifiers besides CFTR modulate the frequency and severity of the disease. One example is

innate immunity by facilitating phagocytosis of microorganisms. Polymorphisms in one or both mannan-binding lectin alleles that result in lower circulating levels of the protein are associated with a threefold higher risk of end-stage lung disease, as well as an increased burden of chronic bacterial infections.[20]

Carriers

Up to one in 25 individuals of Northern European ancestry is considered a

genetic carrier.[52] The disease appears only when two of these carriers have children, as each pregnancy between them has a 25% chance of producing a child with the disease. Although only about one of every 3,000 newborns of the affected ancestry has CF, since the CFTR gene's discovery in 1989, over 2,000 variants have been identified, but only about 700 of these have been recognized as responsible for causing CF.[53] Current tests look for the most common mutations.[52]

The mutant alleles screened by the test vary according to a person's ethnic group or by the occurrence of CF already in the family. More than 10 million Americans, including one in 25 white Americans, are carriers of one mutant allele of the CF gene. CF is present in other races, though not as frequently as in white individuals. About one in 46 Hispanic Americans, one in 65 African Americans, and one in 90 Asian Americans carry a mutation of the CF gene.[52]

Pathophysiology

The CFTR protein is a channel protein that controls the flow of H2O and Cl− ions in and out of cells inside the lungs. When the CFTR protein is working correctly, ions freely flow in and out of the cells. However, when the CFTR protein is malfunctioning, these ions cannot flow out of the cell due to a blocked channel. This causes cystic fibrosis, characterized by the buildup of thick mucus in the lungs.

The CFTR gene regulates the transport of salts and water through cell membranes, providing instructions for creating a pathway that allows the passage of chloride ions.[54] A mutation in the CFTR gene can impair the normal function of chloride channels, leading to abnormal transport of chloride ions and water, resulting in the formation of thick and abnormal mucus.[55]

In the pancreatic duct chloride transport occurs through the voltage-gated chloride channels influenced by CFTR (Cystic Fibrosis transmembrane conductance regulator). These channels are localised in the apical membrane of epithelial cells in the pancreatic duct.[56]

Several mutations in the CFTR gene can occur, and different mutations cause different defects in the CFTR protein, sometimes causing a milder or more severe disease. These protein defects are also targets for drugs which can sometimes restore their function.

ΔF508-CFTR gene mutation, which occurs in >90% of patients in the U.S., creates a protein that does not fold normally and is not appropriately transported to the cell membrane, resulting in its degradation.[57]

Other mutations result in proteins that are too short (truncated) because

production is ended prematurely. Other mutations produce proteins that do not use energy (in the form of ATP) normally, do not allow chloride, iodide, and thiocyanate to cross the membrane appropriately,[58] and degrade faster than normal. Mutations may also lead to fewer copies of the CFTR protein being produced.[21]

The protein created by this gene is anchored to the outer membrane of cells in the sweat glands, lungs, pancreas, and all other remaining exocrine glands in the body. The protein spans this membrane and acts as a channel connecting the inner part of the cell (cytoplasm) to the surrounding fluid. This channel is primarily responsible for controlling the movement of halide anions from inside to outside of the cell; however, in the sweat ducts, it facilitates the movement of chloride from the sweat duct into the cytoplasm. When the CFTR protein does not resorb ions in sweat ducts, chloride, and thiocyanate[59] released from sweat glands are trapped inside the ducts and pumped to the skin.

Additionally

cations to cross into the cell. Sodium is the most common cation in the extracellular space. The excess chloride within sweat ducts prevents sodium resorption by epithelial sodium channels and the combination of sodium and chloride creates the salt, which is lost in high amounts in the sweat of individuals with CF. This lost salt forms the basis for the sweat test.[21]

Most of the damage in CF is due to blockage of the narrow passages of affected organs with thickened secretions. These blockages lead to remodeling and infection in the lung, damage by accumulated digestive enzymes in the pancreas, blockage of the intestines by thick feces, etc. Several theories have been posited on how the defects in the protein and cellular function cause the clinical effects. The current theory suggests that defective ion transport leads to dehydration in the airway epithelia, thickening mucus.[62] In airway epithelial cells, the cilia exist in between the cell's apical surface and mucus in a layer known as airway surface liquid (ASL). The flow of ions from the cell and into this layer is determined by ion channels such as CFTR. CFTR allows chloride ions to be drawn from the cell and into the ASL, but it also regulates another channel called ENac, which allows sodium ions to leave the ASL and enter the respiratory epithelium. CFTR normally inhibits this channel, but if the CFTR is defective, then sodium flows freely from the ASL and into the cell.[citation needed]

As water follows sodium, the depth of ASL will be depleted and the cilia will be left in the mucous layer.[63] As cilia cannot effectively move in a thick, viscous environment, mucociliary clearance is deficient and a buildup of mucus occurs, clogging small airways.[64] The accumulation of more viscous, nutrient-rich mucus in the lungs allows bacteria to hide from the body's immune system, causing repeated respiratory infections. The presence of the same CFTR proteins in the pancreatic duct and sweat glands in the skin also causes symptoms in these systems.[citation needed]

Chronic infections

The lungs of individuals with cystic fibrosis are colonized and infected by bacteria from an early age. These bacteria, which often spread among individuals with CF, thrive in the altered mucus, which collects in the small airways of the lungs. This mucus leads to the formation of bacterial microenvironments known as biofilms that are difficult for immune cells and antibiotics to penetrate. Viscous secretions and persistent respiratory infections repeatedly damage the lungs by gradually remodeling the airways, which makes infection even more difficult to eradicate.[65] The natural history of CF lung infections and airway remodeling is poorly understood, largely due to the immense spatial and temporal heterogeneity both within and between the microbiomes of CF patients.[66]

Over time, the types of bacteria and their characteristics change in individuals with CF. In the initial stage, common bacteria such as S. aureus and H. influenzae colonize and infect the lungs.

resistance to commonly used antibiotics. Pseudomonas can develop special characteristics that allow the formation of large colonies, known as "mucoid" Pseudomonas, which are rarely seen in people who do not have CF.[65] Scientific evidence suggests the interleukin 17 pathway plays a key role in resistance and modulation of the inflammatory response during P. aeruginosa infection in CF.[67] In particular, interleukin 17-mediated immunity plays a double-edged activity during chronic airways infection; on one side, it contributes to the control of P. aeruginosa burden, while on the other, it propagates exacerbated pulmonary neutrophilia and tissue remodeling.[67]

Infection can spread by passing between different individuals with CF.[68] In the past, people with CF often participated in summer "CF camps" and other recreational gatherings.[69][70] Hospitals grouped patients with CF into common areas and routine equipment (such as nebulizers)[71] was not sterilized between individual patients.[72] This led to the transmission of more dangerous strains of bacteria among groups of patients. As a result, individuals with CF are now routinely isolated from one another in the healthcare setting, and healthcare providers are encouraged to wear gowns and gloves when examining patients with CF to limit the spread of virulent bacterial strains.[73]

CF patients may also have their airways chronically colonized by filamentous fungi (such as Aspergillus fumigatus,

Scedosporium prolificans (chronic airway-colonizers); some filamentous fungi such as Penicillium emersonii and Acrophialophora fusispora are encountered in patients almost exclusively in the context of CF.[74] Defective mucociliary clearance characterizing CF is associated with local immunological disorders. In addition, prolonged therapy with antibiotics and corticosteroid treatments may also facilitate fungal growth. Although the clinical relevance of the fungal airway colonization is still a matter of debate, filamentous fungi may contribute to the local inflammatory response and therefore to the progressive deterioration of the lung function, as often happens with allergic bronchopulmonary aspergillosis – the most common fungal disease in the context of CF, involving a Th2-driven immune response to Aspergillus species.[74][75]

Diagnosis

The location of the CFTR gene on chromosome 7

Diagnosis of CF is initially based on clinical findings indicative of respiratory diseases, various digestive problems, meconium ileus, and more. Definitive diagnosis may involve genetic testing based on family history or chloride concentration testing in sweat, which is relatively high (>60mEq/L) in individuals with CF.

In many localities all newborns are screened for cystic fibrosis within the first few days of life, typically by

CFTR is dysfunctional; the person is then diagnosed with cystic fibrosis.[16]: Diagnosis and Assessment [note 1] Genetic testing is also available to identify the CFTR mutations typically associated with cystic fibrosis. Many laboratories can test for the 30–96 most common CFTR mutations, which can identify over 90% of people with cystic fibrosis.[16]
: Diagnosis and Assessment 

People with CF have less thiocyanate and hypothiocyanite in their saliva[78] and mucus (Banfi et al.). In the case of milder forms of CF, transepithelial potential difference measurements can be helpful. CF can also be diagnosed by the identification of mutations in the CFTR gene.[79]

In many cases, a parent makes the diagnosis because the infant tastes salty.

false positives, CF screening in newborns can be controversial.[80][81]

By 2010 every US state had instituted newborn screening programs[82] and as of 2016 21 European countries had programs in at least some regions.[83]

Prenatal

Women who are

pregnant or couples planning a pregnancy can have themselves tested for the CFTR gene mutations to determine the risk that their child will be born with CF. Testing is typically performed first on one or both parents and, if the risk of CF is high, testing on the fetus is performed. The American College of Obstetricians and Gynecologists recommends all people thinking of becoming pregnant be tested to see if they are a carrier.[84]

Because the development of CF in the fetus requires each parent to pass on a mutated copy of the CFTR gene and because CF testing is expensive, testing is often performed initially on one parent. If testing shows that the parent is a CFTR gene mutation carrier, the other parent is tested to calculate the risk that their children will have CF. CF can result from more than a thousand different mutations.[49] As of 2016, typically only the most common mutations are tested for, such as ΔF508.[49] Most commercially available tests look for 32 or fewer different mutations. If a family has a known uncommon mutation, specific screening for that mutation can be performed. Because not all known mutations are found on current tests, a negative screen does not guarantee that a child will not have CF.[85]

During pregnancy, testing can be performed on the placenta (chorionic villus sampling) or the fluid around the fetus (amniocentesis). However, chorionic villus sampling has a risk of fetal death of one in 100 and amniocentesis of one in 200;[86] a recent study has indicated this may be much lower, about one in 1,600.[87]

Economically, for carrier couples of cystic fibrosis, when comparing preimplantation genetic diagnosis (PGD) with natural conception (NC) followed by prenatal testing and abortion of affected pregnancies, PGD provides net economic benefits up to a maternal age around 40 years, after which NC, prenatal testing, and abortion have a higher economic benefit.[88]

Management

Treatment for CF is diverse, tailored to different symptoms, and includes various devices, inhalation medications to alleviate respiratory difficulties, oral enzyme supplements to address exocrine pancreatic insufficiency, and, in some cases, surgical interventions for conditions such as meconium ileus.[89] While treatment alleviates symptoms and prevents potential complications, there is currently no cure for the disease.

The management of CF has improved significantly over the past 70 years. While infants born with it 70 years ago would have been unlikely to live beyond their first year, infants today are likely to live well into adulthood. Advances in the treatment of cystic fibrosis have meant that people with cystic fibrosis can live a fuller life less encumbered by their condition. The cornerstones of management are the proactive treatment of

reproductive organs (including assisted reproductive technology), and psychological support.[93]

The most consistent aspect of therapy in CF is limiting and treating the lung damage caused by thick mucus and infection, with the goal of maintaining

probiotics, which are thought to be able to correct intestinal dysbiosis and inflammation, but the clinical trial evidence regarding the effectiveness of probiotics for reducing pulmonary exacerbations in people with CF is uncertain.[95]

Antibiotics

Many people with CF are on one or more antibiotics at all times, even when healthy, to

Port-a-Cath. Inhaled therapy with antibiotics such as tobramycin, colistin, and aztreonam is often given for months at a time to improve lung function by impeding the growth of colonized bacteria.[96][97][98] Inhaled antibiotic therapy helps lung function by fighting infection, but also has significant drawbacks such as development of antibiotic resistance, tinnitus, and changes in the voice.[99] Inhaled levofloxacin may be used to treat Pseudomonas aeruginosa in people with cystic fibrosis who are infected.[100]

Antibiotics by mouth such as ciprofloxacin or azithromycin are given to help prevent infection or to control ongoing infection.[101] The aminoglycoside antibiotics (e.g. tobramycin) used can cause hearing loss, damage to the balance system in the inner ear or kidney failure with long-term use.[102] To prevent these side-effects, the amount of antibiotics in the blood is routinely measured and adjusted accordingly.[103]

Currently, no reliable clinical trial evidence shows the effectiveness of antibiotics for pulmonary exacerbations in people with cystic fibrosis and Burkholderia cepacia complex[104] or for the use of antibiotics to treat nontuberculous mycobacteria in people with CF.[105]

Pseudomonas aeruginosa

The early management of Pseudomonas aeruginosa infection is usually suggested using nebulised antibiotics with or without oral antibiotics to remove the bacteria from the person's airways for some time.[106] When choosing antibiotics to treat lung infections caused by Pseudomonas aeruginosa in people with cystic fibrosis, it is still unclear whether the choice of antibiotics should be based on the results of testing antibiotics separately (one at a time) or in combination with each other.[107] It is also unclear if these treatment approaches for the Pseudomonas aeruginosa infection improve the person's quality of life or lifespan.[106] The negative side effects of antibiotics for this infection are also poorly studied.[106] Intravenous antibiotic therapy to treat Pseudomonas aeruginosa infections is not any better than antibiotics taken orally.[106]

Methicillin-resistant Staphylococcus aureus

Methicillin-resistant Staphylococcus aureus (MRSA) infections can be dangerous for people with cystic fibrosis and can worsen lung damage leading to more rapid decline. Early antibiotic treatment is standard; however, further research is needed to determine longer-term effects and benefits (3–6 months after the treatment or longer) and survival rates associated with different treatment options.[108]

Antibiotic adjuvant therapy

Factors related to antibiotic use, the chronicity of the disease, and the emergence of resistant bacteria demand more exploration for different strategies such as antibiotic

zinc supplements, or KB001-A.[109]

Other medication

See also: Cystic fibrosis transmembrane conductance regulator § Drug target

Aerosolized medications that help loosen secretions include

hypertonic saline.[110] Dornase is a recombinant human deoxyribonuclease, which breaks down DNA in the sputum, thus decreasing its viscosity.[111] Dornase alpha improves lung function and probably decreases the risk of exacerbations but there is insufficient evidence to know if it is more or less effective than other similar medications.[112] Dornase alpha may improve lung function; however, there is no strong evidence that it is better than other hyperosmolar therapies.[112]

Pneumococcal vaccination has not been studied as of 2014.[115] As of 2014, there is no clear evidence from randomized controlled trials that the influenza vaccine is beneficial for people with cystic fibrosis.[116]

F508del mutation.[121]

In 2019, the

elexacaftor/ivacaftor/tezacaftor, marketed as Trikafta and described as modulator therapy,[122] was approved for CF patients over the age of 12 in the United States,[123][124] extended to age 6 in 2021.[125] In Europe this drug was approved in 2020 and marketed as Kaftrio.[126] It is used in those who have a f508del mutation, found in about 90% of patients with cystic fibrosis.[123][127] According to the Cystic Fibrosis Foundation, "this medicine represents the single greatest therapeutic advancement in the history of CF, offering a treatment for the underlying cause of the disease that could eventually bring modulator therapy to 90 percent of people with CF."[122] In a clinical trial, participants who were administered the combination drug experienced a subsequent 63% decrease in pulmonary exacerbations and a 41.8 mmol/L decrease in sweat chloride concentration.[128] By mitigating a repertoire of symptoms associated with cystic fibrosis, the combination drug significantly improved quality-of-life metrics among patients with the disease as well.[128][122] The combination drug is also known to interact with CYP3A inducers,[129] such as carbamazepine used in the treatment of bipolar disorder, causing elexafaftor/ivacaftor/tezacaftor to circulate in the body at decreased concentrations. As such, concurrent use is not recommended.[130] The list price in the US is going to be $311,000 per year;[131] however, insurance may cover much of the cost of the drug.[132]

Ursodeoxycholic acid, a bile salt, has been used; however, a 2021 study aimed at evaluating whether the incidence of severe liver disease differed between CF centers routinely prescribing or not prescribing UDCA found no reduction in portal hypertension.[133]

The combination vanzacaftor/tezacaftor/deutivacaftor (Alyftrek) was approved for medical use in the United States in December 2024.[134]

Nutrient supplementation

It is uncertain whether

beta-carotene supplementation has any effect on eye and skin problems caused by vitamin A deficiency.[135]

There is no strong evidence that people with cystic fibrosis can prevent osteoporosis by increasing their intake of vitamin D.[136]

For people with vitamin E deficiency and cystic fibrosis, there is evidence that vitamin E supplementation may improve vitamin E levels, although it is still uncertain what effect supplementation has on vitamin E-specific deficiency disorders or on lung function.[137]

Robust evidence regarding the effects of vitamin K supplementation in people with cystic fibrosis is lacking as of 2020.[138]

Various studies have examined the effects of omega-3 fatty acid supplementation for people with cystic fibrosis but the evidence is uncertain whether it has any benefits or adverse effects.[139]

Procedures

Several mechanical techniques are used to dislodge sputum and encourage its expectoration. One technique good for short-term airway clearance is

biphasic cuirass ventilation, and associated clearance mode available in such devices, integrate a cough assistance phase, as well as a vibration phase for dislodging secretions. These are portable and adapted for home use.[12]

Another technique is positive expiratory pressure physiotherapy which consists of providing back pressure to the airways during expiration. This effect is provided by devices that consist of a mask or a mouthpiece in which resistance is applied only during the expiration phase.[140] Operating principles of this technique seem to be the increase of gas pressure behind mucus through collateral ventilation along with a temporary increase in functional residual capacity preventing the early collapse of small airways during exhalation.[141][142]

As lung disease worsens, mechanical breathing support may become necessary. Individuals with CF may need to wear special masks at night to help push air into their lungs. These machines, known as

tracheostomy) to enable breathing supported by a ventilator.[145][146]

For children, preliminary studies show

massage therapy may help people and their families' quality of life.[147]

Some lung infections require surgical removal of the infected part of the lung. If this is necessary many times, lung function is severely reduced.[148] The most effective treatment options for people with CF who have spontaneous or recurrent pneumothoraces is not clear.[149]

Transplantation

Lung transplantation may become necessary for individuals with CF as lung function and exercise tolerance decline. Although single lung transplantation is possible in other diseases, individuals with CF must have both lungs replaced because the remaining lung might contain bacteria that could infect the transplanted lung. A pancreatic or liver transplant may be performed at the same time to alleviate liver disease and/or diabetes.[150] Lung transplantation is considered when lung function declines to the point where assistance from mechanical devices is required or someone's survival is threatened.[151] According to Merck Manual, "bilateral lung transplantation for severe lung disease is becoming more routine and more successful with experience and improved techniques. Among adults with CF, median survival posttransplant is about 9 years."[152]

Other aspects

Intracytoplasmic sperm injection can be used to provide fertility for men with cystic fibrosis.

Newborns with intestinal obstruction typically require surgery, whereas adults with distal intestinal obstruction syndrome typically do not. Treatment of pancreatic insufficiency by replacement of missing digestive enzymes allows the duodenum to properly absorb nutrients and vitamins that would otherwise be lost in the feces. However, the best dosage and form of pancreatic enzyme replacement are unclear, as are the risks and long-term effectiveness of this treatment.[153]

So far, no large-scale research involving the incidence of

coronary heart disease in adults with cystic fibrosis has been conducted. This is likely because the vast majority of people with cystic fibrosis do not live long enough to develop clinically significant atherosclerosis or coronary heart disease.[154]

antidiabetic drugs are sometimes used, the recommended treatment is the use of insulin injections or an insulin pump,[156] and, unlike in type 1 and 2 diabetes, dietary restrictions are not recommended.[40] While Stenotrophomonas maltophilia is relatively common in people with cystic fibrosis, the evidence about the effectiveness of antibiotics for S. maltophilia is uncertain.[157]

Bisphosphonates taken by mouth or intravenously can be used to improve bone mineral density in people with cystic fibrosis, but there is no proof that this reduces fractures or increases survival rates.[158] When taking bisphosphates intravenously, adverse effects such as pain and flu-like symptoms can be an issue.[158] The adverse effects of bisphosphates taken by mouth on the gastrointestinal tract are unknown.[158]

Poor growth may be avoided by insertion of a feeding tube for increasing food energy through supplemental feeds or by administration of injected growth hormone.[159]

Sinus infections are treated by prolonged courses of antibiotics. The development of nasal polyps or other chronic changes within the nasal passages may severely limit airflow through the nose, and over time reduce the person's sense of smell. Sinus surgery is often used to alleviate nasal obstruction and to limit further infections. Nasal steroids such as fluticasone propionate are used to decrease nasal inflammation.[160]

Female infertility may be overcome by assisted reproduction technology, particularly embryo transfer techniques. Male infertility caused by the absence of the vas deferens may be overcome with testicular sperm extraction, collecting sperm cells directly from the testicles. If the collected sample contains too few sperm cells to likely have spontaneous fertilization, intracytoplasmic sperm injection can be performed.[161] Third party reproduction is also a possibility for women with CF. Whether taking antioxidants affects outcomes is unclear.[162]

Physical exercise is usually part of outpatient care for people with cystic fibrosis.[163] Aerobic exercise seems to be beneficial for aerobic exercise capacity, lung function, and health-related quality of life; however, the quality of the evidence was poor.[163]

Due to the use of aminoglycoside antibiotics, ototoxicity is common. Symptoms may include "tinnitus, hearing loss, hyperacusis, aural fullness, dizziness, and vertigo".[164]

Gastrointestinal

Problems with the gastrointestinal system including constipation and obstruction of the gastrointestinal tract including distal intestinal obstruction syndrome are frequent complications for people with cystic fibrosis.[34] Treatment of gastrointestinal problems is required in order to prevent a complete obstruction, reduce other CF symptoms, and improve the quality of life.[34] While stool softeners, laxatives, and prokinetics (GI-focused treatments) are often suggested, there is no clear consensus from experts as to which approach is the best and comes with the least risks.[34] Mucolytics or systemic treatments aimed at dysfunctional CFTR are also sometimes suggested to improve symptoms.[165] The evidence supporting these recommendations is very weak and more research is needed to understand how to prevent and treat GI problems in people with CF.[165] In addition, there is a risk of gastrointestinal malignancy, especially in the transplanted patient, and screening procedures may be considered at an earlier age.[166]

Prognosis

The prognosis for cystic fibrosis has improved due to earlier diagnosis through screening and better treatment and access to health care. In 1959, the median age of survival of children with CF in the United States was six months.[167] In 2010, survival is estimated to be 37 years for women and 40 for men.[168] In Canada, median survival increased from 24 years in 1982 to 47.7 in 2007.[169] In the United States those born with CF in 2016 have a predicted life expectancy of 47.7 when cared for in specialty clinics.[170] Due to the recent development of new treatments, such as CFTR modulators, life expectancy has increased rapidly during recent years. In 2020 the median predicted life expectancy was around 59 years, although there are uncertainties in the estimates due to the low number of annual deaths for persons with cystic fibrosis.[171]

In the US, of those with CF who are more than 18 years old as of 2009, 92% had graduated from high school, 67% had at least some college education, 15% were disabled, 9% were unemployed, 56% were single, and 39% were married or living with a partner.[172]

Quality of life

Chronic illnesses can be difficult to manage. CF is a chronic illness that affects the "digestive and respiratory tracts resulting in generalized malnutrition and chronic respiratory infections".[173] The thick secretions clog the airways in the lungs, which often cause inflammation and severe lung infections.[174][175] If it is compromised, it affects the quality of life of someone with CF and their ability to complete such tasks as everyday chores.[citation needed]

According to Schmitz and Goldbeck (2006), CF significantly increases emotional stress on both the individual and the family, "and the necessary time-consuming daily treatment routine may have further negative effects on quality of life".[176] However, Havermans and colleagues (2006) have established that young outpatients with CF who have participated in the Cystic Fibrosis Questionnaire-Revised "rated some quality of life domains higher than did their parents".[177] Consequently, outpatients with CF have a more positive outlook for themselves. As Merck Manual notes, "with appropriate support, most patients can make an age-appropriate adjustment at home and school. Despite myriad problems, the educational, occupational, and marital successes of patients are impressive."[152]

Furthermore, there are many ways to enhance the quality of life in CF patients. Exercise is promoted to increase lung function. Integrating an exercise regimen into the CF patient's daily routine can significantly improve quality of life.[178] No definitive cure for CF is known, but diverse medications are used, such as mucolytics, bronchodilators, steroids, and antibiotics, that have the purpose of loosening mucus, expanding airways, decreasing inflammation, and fighting lung infections, respectively.[179]

Epidemiology

Mutation Frequency
worldwide[180]
ΔF508 66–70%[20]
G542X 2.4%
G551D 1.6%
N1303K 1.3%
W1282X 1.2%
All others 27.5%

Cystic fibrosis is the most common life-limiting autosomal recessive disease among people of European heritage.[181] In the United States, about 30,000 individuals have CF; most are diagnosed by six months of age. In Canada, about 4,000 people have CF.[182] Around 1 in 25 people of European descent, and one in 30 of white Americans,[183] is a carrier of a CF mutation. Although CF is less common in these groups, roughly one in 46 Hispanics, one in 65 Africans, and one in 90 Asians carry at least one abnormal CFTR gene.[184][185] Ireland has the world's highest prevalence of CF, at one in 1353;[186] Japan's prevalence of CF is among the lowest in the world, at one in 350,000.[187]

Although technically a rare disease, CF is ranked as one of the most widespread life-shortening genetic diseases. It is most common among nations in the Western world. An exception is Finland, where only one in 80 people carries a CF mutation.[188] The World Health Organization states, "In the European Union, one in 2000–3000 newborns is found to be affected by CF".[189] In the United States, one in 3,500 children is born with CF.[190] In 1997, about one in 3,300 white children in the United States was born with CF. In contrast, only one in 15,000 African American children have it, and in Asian Americans, the rate was even lower at one in 32,000.[191]

Cystic fibrosis is diagnosed equally in males and females. For reasons that remain unclear, data have shown that males tend to have a longer life expectancy than females,[192][193] though recent studies suggest this gender gap may no longer exist, perhaps due to improvements in health care facilities.[194][195] A recent study from Ireland identified a link between the female hormone estrogen and worse outcomes in CF.[196]

The distribution of CF alleles varies among populations. The frequency of ΔF508 carriers has been estimated at one in 200 in northern Sweden, one in 143 in Lithuanians, and one in 38 in Denmark. No ΔF508 carriers were found among 171 Finns and 151

Saami people.[197] ΔF508 does occur in Finland, but it is a minority allele there. CF is known to occur in only 20 families (pedigrees) in Finland.[198]

Evolution

The ΔF508 mutation is estimated to have occurred up to 52,000 years ago.

evolutionary trade-off known as heterozygote advantage
. Resistance to the following have all been proposed as possible sources of heterozygote advantage:

  • Cholera: With the discovery that cholera toxin requires normal host CFTR proteins to function properly, it was hypothesized that carriers of mutant CFTR alleles benefited from resistance to cholera and other causes of diarrhea.[200][201] Further studies have not confirmed this hypothesis.[202][203]
  • Salmonella Typhi into cells,[204] suggesting that carriers of mutant CFTR genes might be resistant to typhoid fever. No in vivo study has yet confirmed this. In both cases, the low level of cystic fibrosis outside of Europe, in places where both cholera and typhoid fever are endemic
    , is not immediately explicable.
  • Diarrhea: The prevalence of CF in Europe might be connected with the development of cattle domestication. In this hypothesis, carriers of a single mutant CFTR allele had some protection from diarrhea caused by lactose intolerance, before the mutations that created lactose tolerance appeared.[205]
  • Tuberculosis: Another possible explanation is that carriers of the mutant allele could have some resistance to tuberculosis.[206][207] This hypothesis is based on the thesis that CFTR mutant allele carriers have insufficient action in one of their enzymes – arylsulphatase – which is necessary for Mycobacterium tuberculosis virulence. As M. tuberculosis would use its host's sources to affect the individual, and due to the lack of enzyme it could not present its virulence, being a carrier of CFTR mutant allele could provide resistance against tuberculosis.[208]

History

See also: List of people diagnosed with cystic fibrosis
Dorothy Hansine Andersen first described cystic fibrosis in 1938.

CF is supposed to have appeared about 3,000 BC because of the migration of people, gene mutations, and new conditions in nourishment.[209] Although the entire clinical spectrum of CF was not recognized until the 1930s, certain aspects of CF were identified much earlier. Indeed, literature from Germany and Switzerland in the 18th century warned "Wehe dem Kind, das beim Kuß auf die Stirn salzig schmeckt, es ist verhext und muss bald sterben" ("Woe to the child who tastes salty from a kiss on the forehead, for he is bewitched and soon must die"), recognizing the association between the salt loss in CF and illness.[209]

In the 19th century,

celiac disease, cystic fibrosis of the pancreas, and bronchiectasis.[210]

In 1938,

American Journal of Diseases of Children. She was the first to describe the characteristic cystic fibrosis of the pancreas and to correlate it with the lung and intestinal disease prominent in CF.[15] She also first hypothesized that CF was a recessive disease and first used pancreatic enzyme replacement to treat affected children. In 1952, Paul di Sant'Agnese discovered abnormalities in sweat electrolytes; a sweat test was developed and improved over the next decade.[211]

The first linkage between CF and another marker (

Francis Collins, Lap-Chee Tsui, and John R. Riordan on the seventh chromosome.[213] Subsequent research has found over 1,000 different mutations that cause CF.[214]

Because mutations in the CFTR gene are typically small,

Hospital for Sick Children in Toronto that discovered the gene responsible for CF.[216] CF represents a classic example of how a human genetic disorder was elucidated strictly by the process of forward genetics.[215][217]

Research

People with CF may be listed in a disease registry that allows researchers and doctors to track health results and identify candidates for clinical trials.[218]

Gene therapy

Gene therapy has been explored as a potential cure for CF. Results from clinical trials have shown limited success as of 2016, and using gene therapy as routine therapy is not suggested.[219] A small study published in 2015 found a small benefit.[220]

The focus of much CF gene therapy research is aimed at trying to place a normal copy of the CFTR gene into affected cells. Transferring the normal CFTR gene into the affected epithelial cells would result in the production of functional CFTR protein in all target cells, without adverse reactions or an inflammation response; this is known as somatic cell therapy. To prevent the lung manifestations of CF, only 5–10% of the normal amount of CFTR gene expression is needed.[221] Multiple approaches have been tested for gene transfer, such as liposomes and viral vectors in animal models and clinical trials. However, both methods were found to be relatively inefficient treatment options,[222] mainly because very few cells take up the vector and express the gene, so the treatment has little effect. Additionally, problems have been noted in cDNA recombination, such that the gene introduced by the treatment is rendered unusable.[223] There has been a functional repair in culture of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients.[224]

Bacteriophage therapy

Bacteriophage therapy (phage therapy) is being studied for multidrug-resistant bacteria in people with CF.[225][226] Bacteriophage therapy is a treatment method that uses viruses, known as bacteriophages, to target and destroy harmful bacteria in the body. Unlike antibiotics, which can kill a wide range of bacteria and potentially disrupt the body's normal flora, phage therapy is highly specific, targeting only the harmful bacteria while leaving the beneficial ones unharmed. As such, bacteriophage therapy is a promising alternative for treating infections caused by multidrug-resistant bacteria, such as Staphylococcus aureus, Haemophilus influenzae, and Pseudomonas aeruginosa in CF patients, which are often protected by biofilms and thus resistant to conventional antibiotics.[227][228][229]

Bacteriophage therapy uses viruses as antimicrobial agents to overcome the antibiotic resistance in bacteria with biofilms[230] Phage therapy is used to treat the Pseudomonas aeruginosa infection in the lungs, which is frequently seen in cystic fibrosis patients, as these bacteria produce biofilms which give them multi-drug resistance.[231]

Gene modulators

Several small molecules that aim at compensating various mutations of the CFTR gene are under development. CFTR

modulator therapies has been used instead of other types of genetic therapies. These therapies focus on the expression of a genetic mutation instead of the mutated gene itself. Modulators are split into two classes: potentiators and correctors. Potentiators act on the CFTR ion channels that are embedded in the cell membrane, and these drugs help open up the channel to allow transmembrane flow. Correctors are meant to assist in the transportation of nascent proteins, proteins that are formed by ribosomes before it is morphed into a specific shape, to the cell surface to be implemented into the cell membrane.[232]

Most target the transcription stage of genetic expression. One approach has been to try and develop medication that get the ribosome to overcome the stop codon and produce a full-length CFTR protein. About 10% of CF results from a premature stop codon in the DNA, leading to early termination of protein synthesis and truncated proteins. These drugs target nonsense mutations such as G542X, which consists of the amino acid glycine in position 542 being replaced by a stop codon. Aminoglycoside antibiotics interfere with protein synthesis and error correction. In some cases, they can cause the cell to overcome a premature stop codon by inserting a random amino acid, thereby allowing the expression of a full-length protein. Future research for these modulators is focused on the cellular targets that can be affected by a change in a gene's expression. Otherwise, genetic therapy will be used as a treatment when modulator therapies do not work given that 10% of people with cystic fibrosis are not affected by these drugs.[233]

Elexacaftor/ivacaftor/tezacaftor was approved in the United States in 2019 for cystic fibrosis.[234] This combination of previously developed medicines can treat up to 90% of people with cystic fibrosis.[232][234] This medication restores some effectiveness of the CFTR protein so that it can work as an ion channel on the cell's surface.[235]

Ecological therapy

It has previously been shown that inter-species interactions are an important contributor to the pathology of CF lung infections. Examples include the production of antibiotic degrading enzymes such as β-lactamases and the production of metabolic by-products such as short-chain fatty acids (SCFAs) by anaerobic species, which can enhance the pathogenicity of traditional pathogens such as Pseudomonas aeruginosa.[236] Due to this, it has been suggested that the direct alteration of CF microbial community composition and metabolic function would provide an alternative to traditional antibiotic therapies.[66]

Antisense therapy

Antisense therapy is being researched to treat a subset of mutations that have limited or no response to CFTR modulators.[237] Such mutations fall into two classes: splicing (e.g., c.3718-2477C>T) and nonsense (e.g., G542X, W1282X), both of which result in very low expression of CFTR protein, although the protein itself is usually unaffected. This is contrary to the more common mutations such as ΔF508 which have normal CFTR expression but in a non-functional form. Modulators serve only to correct these aberrant proteins and are of little to no benefit in the case of insufficient expression. Antisense oligonucleotides (ASOs) can solve this problem through the promotion of mRNA degradation or by changing pre-mRNA splicing, nonsense-mediated mRNA decay, or translation, thus increasing CFTR expression.

Society and culture

Explanatory notes

  1. millimoles/liter. Those with less than 30 millimoles/liter sweat chloride are unlikely to develop cystic fibrosis. For people with intermediate sweat chloride between 30 and 59 millimoles/liter, they recommend additional genetic testing.[77]

References

  1. ^
    S2CID 46011502
    .
  2. ISBN 9781439801826. Archived
    from the original on 8 September 2017.
  3. ^
    PMID 23466339
    .
  4. S2CID 235327978
    .
  5. ^
    PMID 26371812
    .
  6. PMID 37211214
    .
  7. ^ Sencen L. "Cystic Fibrosis". NORD (National Organization for Rare Disorders). Retrieved 29 July 2022.
  8. ^ "Orphanet: Cystic fibrosis". www.orpha.net. Retrieved 29 July 2022.
  9. ^
    ISBN 978-1-4441-1369-3. Archived
    from the original on 8 September 2017.
  10. ISBN 978-0-8036-2975-2. Archived
    from the original on 8 September 2017.
  11. PMID 14734689
    .
  12. ^
    PMID 37042825
    .
  13. PMID 24115706
    .
  14. PMID 28944141
    .
  15. ^
    doi:10.1001/archpedi.1938.01980140114013
    .
  16. ^
    ISBN 978-0-323-56890-6
    .
  17. S2CID 235327978
    .
  18. ^ Reaves J, Wallace G (2010). "Unexplained bruising: weighing the pros and cons of possible causes". Consultant for Pediatricians. 9: 201–2. Archived from the original on 22 February 2020. Retrieved 22 February 2020.
  19. PMID 20675678
    .
  20. ^
    ISBN 978-1-4160-2973-1
    .
  21. ^
    PMID 15888700
    .
  22. PMID 14726455
    .
  23. PMID 16266669
    .
  24. PMID 20209279
    .
  25. PMID 15626248
    .
  26. PMID 1527348
    .
  27. PMID 31353045
    .
  28. PMID 16131979
    .
  29. ISBN 978-3135450070
    .
  30. PMID 9725922
    .
  31. PMID 13578072
    .
  32. ^
    PMID 26857772
    .
  33. PMID 1755649
    .
  34. ^
    PMID 34936085
    .
  35. PMID 15582124
    .
  36. PMID 12447862
    .
  37. PMID 1458306
    .
  38. S2CID 27836468
    .
  39. PMID 8039595
    .
  40. ^
    PMID 17724542
    .
  41. PMID 10525552
    .
  42. PMID 11035677
    .
  43. PMID 22709980
    .
  44. S2CID 28860665
    .
  45. S2CID 32289370
    .
  46. PMID 28881097
    .
  47. PMID 32512483
    .
  48. ^ 'CFTR2 Variant List History'
  49. ^
    S2CID 20948144
    .
  50. PMID 9677412
    .
  51. PMID 30097657
    .
  52. ^
    S2CID 7644129
    .
  53. S2CID 261623275
    .
  54. PMID 9922379
    .
  55. S2CID 37254079
    .
  56. ISBN 9789356962897
    .
  57. PMID 24970227
    .
  58. PMID 16934416
    .
  59. PMID 19918082
    .
  60. PMID 17082494
    .
  61. PMID 17204267
    .
  62. PMID 26719229
    .
  63. S2CID 11790119
    .
  64. ISBN 978-0805361179
    .
  65. ^
    PMID 14980298
    .
  66. ^
    PMID 33262240
    .
  67. ^
    PMID 27189736
    .
  68. PMID 1907611
    .
  69. PMID 7684813
    .
  70. PMID 7513755
    .
  71. PMID 8744509
    .
  72. PMID 12775867
    .
  73. PMID 7643943
    .
  74. ^
    PMID 19107638
    .
  75. PMID 18668399
    .
  76. ^ "Newborn Screening for CF". Cystic Fibrosis Foundation. Retrieved 25 January 2022.
  77. S2CID 206410545
    .
  78. PMID 18519245
    .
  79. PMID 9017943
    .
  80. PMID 18718257
    .
  81. PMID 12196308
    .
  82. S2CID 52845580
    .
  83. PMID 28043799
    .
  84. ^ "Carrier Screening in the Age of Genomic Medicine". American College of Obstetricians and Gynecologists. 2017. Archived from the original on 25 February 2017. Retrieved 22 February 2020.
  85. PMID 2014829
    .
  86. S2CID 31237495
    .
  87. S2CID 19081825
    .
  88. PMID 19439290
    .
  89. ^ "Treatment preference among people with cystic fibrosis: the importance of reducing treatment burden". Chest. 162 (6). 2022.
  90. PMID 33792230
    .
  91. ^
    PMID 32234058
    .
  92. PMID 32272478
    .
  93. PMID 18079549
    .
  94. PMID 30707039
    .
  95. PMID 31962375
    .
  96. S2CID 30108514
    .
  97. PMID 15463883
    .
  98. PMID 18658109
    .
  99. PMID 21412868
    .
  100. ^ "Quinsair (levofloxacin)". European Medicines Agency. Archived from the original on 26 December 2016. Retrieved 26 December 2016.
  101. PMID 15752679
    .
  102. PMID 12623858
    .
  103. ^ "Antibiotic resistance". Fact Sheet. World Health Organization. 31 July 2020. Retrieved 24 June 2022.
  104. PMID 32239690
    .
  105. PMID 32521055
    .
  106. ^
    PMID 37268599
    .
  107. PMID 32412092
    .
  108. PMID 36511181
    .
  109. ^
    PMID 32671834
    .
  110. S2CID 26244542
    .
  111. PMID 5694947
    .
  112. ^
    PMID 33735508
    .
  113. PMID 18276176
    .
  114. ^
    PMID 31271656
    .
  115. PMID 25093421
    .
  116. PMID 24604671
    .
  117. ^
    PMID 24656117
    .
  118. S2CID 39537446
    .
  119. ^ "Press Announcements - FDA approves new treatment for cystic fibrosis". FDA. 2 July 2015. Archived from the original on 18 January 2017. Retrieved 16 January 2017.
  120. ^ "FDA approves another Vertex drug for treatment of cystic fibrosis". The Boston Globe. 12 February 2018. Archived from the original on 26 December 2023.
  121. ^ "Tezacaftor (VX-661) for Cystic Fibrosis". Cystic Fibrosis News Today. Archived from the original on 29 September 2018. Retrieved 23 December 2018.
  122. ^ a b c "Statement on FDA approval of Trikafta, the first triple-combination therapy for the most common CF mutation" (Press release). Bethesda, Md.: Cystic Fibrosis Foundation. 21 October 2019. Retrieved 12 August 2020.
  123. ^ a b "Trikafta (elexacaftor, ivacaftor and tezacaftor) FDA Approval History". Drugs.com.
  124. ^ Office of the Commissioner (24 March 2020). "FDA approves new breakthrough therapy for cystic fibrosis". FDA. Retrieved 28 April 2022.
  125. ^ "FDA Accepts Vertex Application for Expansion of Trikafta to Include Children ages 6-11 | Cystic Fibrosis Foundation". www.cff.org. 26 January 2021. Retrieved 28 April 2022.
  126. ^ "NHS England » Landmark NHS deal to open up access to life-changing cystic fibrosis drug". www.england.nhs.uk. 21 August 2020. Retrieved 8 August 2021.
  127. ^ Office of the Commissioner (24 March 2020). "FDA approves new breakthrough therapy for cystic fibrosis". FDA. Retrieved 12 August 2020.
  128. ^
    PMID 31697873
    .
  129. S2CID 30289771
    .
  130. PMID 32265602
    .
  131. ^ "Vertex prices cystic fibrosis combo treatment at $311,000-per-year". Reuters. 21 October 2019. Retrieved 23 October 2019.
  132. ^ "FDA Approves the First New Cystic Fibrosis Treatment in Decades". Good News Network. 3 November 2019. Retrieved 12 August 2020.
  133. doi:10.1016/j.jcf.2021.03.014.{{cite journal}}: CS1 maint: overridden setting (link
    )
  134. ^ "Vertex Announces US FDA Approval of Alyftrek, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis" (Press release). Vertex. 20 December 2024. Retrieved 24 December 2024 – via Business Wire.
  135. PMID 30091146
    .
  136. PMID 24823922
    .
  137. PMID 32892350
    .
  138. PMID 32497260
    .
  139. PMID 32275788
    .
  140. PMID 31774149
    .
  141. PMID 392747
    .
  142. PMID 3899222
    .
  143. ^
    PMID 28218802
    .
  144. PMID 28218802
    .
  145. ^ "Tracheostomy Why it's used". NHS. 3 October 2018. Retrieved 10 May 2020.
  146. ^ Molnar H (11 April 2023). "Types of Tracheostomy Tubes".
  147. PMID 16229132
    .
  148. ^ Leinwand MJ (28 December 2019). Windle ML, Odim J (eds.). "Surgical Treatment of Infections of the Lung, Pleura, and Mediastinum". Medscape. Archived from the original on 5 October 2016.
  149. PMID 23235645
    .
  150. PMID 16298663
    .
  151. PMID 16387803
    .
  152. ^ a b "Cystic Fibrosis - Pediatrics". Merck Manuals Professional Edition. Retrieved 12 August 2020.
  153. PMID 32761612
    .
  154. PMID 27751792
    .
  155. PMID 19651382
    .
  156. PMID 33075159
    .
  157. PMID 32189337
    .
  158. ^
    PMID 36625789
    .
  159. PMID 15756212
    .
  160. S2CID 5606258
    .
  161. PMID 10655317
    .
  162. PMID 25102015
    .
  163. ^
    PMID 35943025
    .
  164. PMID 29471610
    .
  165. ^
    PMID 34936085
    .
  166. PMID 37643818
    .
  167. S2CID 1770759
    .
  168. PMID 25133359
    .
  169. Canadian Cystic Fibrosis Foundation. 2007. Archived from the original
    (PDF) on 15 July 2010. Retrieved 14 March 2010.
  170. ^ "Annual Data Report 2016 Cystic Fibrosis Foundation Patient Registry" (PDF). p. 4. Archived from the original (PDF) on 19 June 2018. Retrieved 19 June 2018.
  171. ^ Cystic Fibrosis Foundation (September 2021). "Patient Registry 2020 Annual Data Report" (PDF). www.cff.org/. Retrieved 26 September 2024.
  172. ^ "Cystic Fibrosis Patient Registry Annual Data Report 2009" (PDF). Cystic Fibrosis Foundation. 2009. Archived from the original (PDF) on 5 January 2012.
  173. PMID 10722612
    .
  174. S2CID 24879334
    .
  175. S2CID 44627706
    .
  176. PMID 16457728
    .
  177. PMID 16398786
    .
  178. PMID 9637933
    .
  179. ^ "Medications". Cystic Fibrosis Canada. 2011. No. 10684-5100 RR0001. Archived from the original on 4 September 2011.
  180. PMID 15665983
    .
  181. ISBN 978-1-118-29370-6. Archived
    from the original on 17 April 2016.
  182. ^ "The Canadian Facts & Figures on Cystic Fibrosis". cysticfibrosis.ca. Archived from the original on 16 June 2013.
  183. ^ "Genetic Carrier Testing". Cystic Fibrosis Foundation. 2007. Archived from the original on 23 March 2010.
  184. PMID 9580754
    .
  185. PMID 9506637
    .
  186. PMID 17955689. Archived from the original
    on 3 December 2013.
  187. PMID 9161949
    .
  188. PMID 11813900
    .
  189. ^ "WHO | Genes and human disease". Who.int. 7 December 2010. Archived from the original on 20 October 2012. Retrieved 23 January 2013.
  190. ISBN 978-0-538-49372-7. Archived
    from the original on 17 April 2016.
  191. ^ "Genetic testing for cystic fibrosis Genetic Testing for Cystic Fibrosis". Consensus Development Conference Statement. National Institutes of Health. 14–16 April 1997. Archived from the original on 27 March 2009.
  192. PMID 9143209
    .
  193. PMID 19033671
    .
  194. PMID 16236961
    .
  195. PMID 19542209
    .
  196. ^ "CF worse for women 'due to effect of estrogen'". The Irish Times. 8 August 2010. Archived from the original on 11 August 2010.
  197. PMID 8039801
    .
  198. S2CID 38364780
    .
  199. PMID 11556136
    .
  200. PMID 7524148
    .
  201. PMID 20110149
    .
  202. PMID 7714835
    .
  203. PMID 11055897
    .
  204. S2CID 5894247
    .
  205. S2CID 4650571
    .
  206. PMID 17015291
    .
  207. S2CID 2346727
    .
  208. PMID 12796199
    .
  209. ^
    PMID 2130674
    .
  210. ^ Fanconi G, Uehlinger E, Knauer C (1936). "Das coeliakiesyndrom bei angeborener zysticher pankreasfibromatose und bronchiektasien". Wien. Med. Wochenschr. 86: 753–756.
  211. S2CID 42514224
    .
  212. S2CID 41143417
    .
  213. S2CID 84566748
    .
  214. PMID 28031875
    .
  215. ^
    PMID 2772657
    .
  216. S2CID 5124983
    .
  217. ISSN 0362-4331
    . Retrieved 27 April 2023.
  218. ^ Freudenheim M (22 December 2009). "Tool in Cystic Fibrosis Fight: A Registry". The New York Times. pp. D1. Archived from the original on 24 May 2013. Retrieved 21 December 2009.
  219. PMID 27314455
    .
  220. PMID 26149841
    .
  221. S2CID 8714332
    .
  222. S2CID 30948229
    .
  223. ^ Online Mendelian Inheritance in Man (OMIM): CYSTIC FIBROSIS; CF - 219700
  224. PMID 24315439
    .
  225. PMID 26213462
    .
  226. PMID 28720345
    .
  227. PMID 37220114
    .
  228. PMID 38378698
    .
  229. PMID 38357445
    .
  230. PMID 17566713
    .
  231. PMID 31130925
    .
  232. ^
    PMID 30917288. ProQuest 2230820891
    .
  233. S2CID 5809127
    . Free full text
  234. ^ a b Office of the Commissioner (24 October 2019). "FDA approves new breakthrough therapy for cystic fibrosis". FDA. Retrieved 13 November 2019.
  235. ^ "CFTR Modulator Therapies". Bethesda, Md.: Cystic Fibrosis Foundation. Retrieved 13 November 2019.
  236. PMID 26774156
    .
  237. PMID 36697233
    .
  238. ^ Hillary Gillis, "Meet Sickboy: The Halifax Podcast Normalizing Death Through Dark Laughs". Vice, 26 July 2017.
Wikimedia Commons has media related to Cystic fibrosis.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Cystic_fibrosis&oldid=1283648154"